01 7Onivyde
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 149
2019 Revenue in Millions : 163
Growth (%) : -8
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 140
2020 Revenue in Millions : 149
Growth (%) : 3
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 174
2021 Revenue in Millions : 140
Growth (%) : 24
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 177
2022 Revenue in Millions : 174
Growth (%) : 1
Irinotecan Hydrochloride Trihydrate
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 71
2016 Revenue in Millions : 0
Growth (%) : New Launch
Irinotecan Hydrochloride Trihydrate
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 124
2017 Revenue in Millions : 64
Growth (%) : 92%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 147
2018 Revenue in Millions : 119
Growth (%) : 23
LOOKING FOR A SUPPLIER?